Effects of Yoga on Sodium-induced Pressor Responses in African American Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05353270 |
Recruitment Status :
Recruiting
First Posted : April 29, 2022
Last Update Posted : April 29, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Blood Pressure | Behavioral: Yoga Behavioral: Waitlist control | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effects of Yoga on Pressor and Endothelial Function in Responses to Sodium Loading in African American Adults |
Actual Study Start Date : | September 1, 2021 |
Estimated Primary Completion Date : | July 1, 2022 |
Estimated Study Completion Date : | July 1, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Yoga
Yoga sessions (35 minutes each) will be performed 5 times weekly for 4 weeks.
|
Behavioral: Yoga
Yoga sessions will be completed 5 times per week for 4 weeks. |
Waitlist control
Waitlisted participants will maintain their normal diet and exercise patterns for 4 weeks prior to rerandomization to the yoga group.
|
Behavioral: Waitlist control
Waitlisted participants will maintain their normal exercise and diet for 4 weeks. After follow up testing at week 4, participants will be rerandomized to the yoga condition. |
- Change in blood pressure from low- to high-sodium dietary conditions [ Time Frame: Measurements will be completed after 3 days of low and 3 days of high sodium intake at baseline and after 4 weeks for both conditions. ]Blood pressure will be measured after 3 days of very low sodium and 3 days of high sodium intake.
- Change in endothelial function from low- to high-sodium dietary conditions. [ Time Frame: Measurements will be completed after 3 days of low- and 3 days of high-sodium intake at baseline and at week 4. ]Flow-mediated dilation will be measured via ultrasound imaging of the upper arm after 3 days of low- and 3 days of high- sodium dietary conditions.
- Change in arterial stiffness from low- to high-sodium dietary conditions. [ Time Frame: Measurements will be completed after 3 days of low- and 3 days of high-sodium intake at baseline and at week 4. ]Cardio-ankle vascular index will be measured after 3 days of low- and 3 days of high-sodium intake.
- Change in urinary sodium excretion from low- to high-sodium dietary conditions. [ Time Frame: Measurements will be completed after 3 days of low- and 3 days of high-sodium intake at baseline and at week 4. ]24-hour urine collection will be completed after 3 days of low- and after 3 days of high-sodium dietary conditions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- African American
- Adults ages 18-60 years
Exclusion Criteria:
- pregnancy or within 60 days postpartum
- having taken blood pressure (including diuretics beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers) or statin medications within the past 3 months (statins have been demonstrated to reduce oxidative stress which could impact flow-mediated dilation);
- infection (viral or other) within the past 4 weeks;
- having adrenal or endocrine tumors (these could impact BP);
- renal disease defined as a glomerular filtration rate (GFR) of less than 60 (creatinine will be tested at initial screening and GFR will be calculated);
- prior myocardial infarction; vii) known coronary heart disease;
- personal history of stroke;
- heart failure;
- cardiac arrhythmias;
- chronic obstructive pulmonary disease;
- recent chest pain or dyspnea;
- orthopedic limitations that preclude the execution of yoga postures;
- current insulin dependence;
- currently taking steroid medications;
- currently undergoing chemotherapy or radiation;
- having practiced yoga or yogic breathing techniques at least once weekly consistently within the past 3 months;
- heat intolerance or electrolyte imbalances (hypo- or hyper-natremia or hypo- or hyper-kalemia).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05353270
United States, Texas | |
Cardiovascular Physiology Laboratory-Texas State University | Recruiting |
San Marcos, Texas, United States, 78666 | |
Contact: Stacy D. Hunter, PhD 512-245-8046 s_h393@txstate.edu | |
Contact s_h393@txstate.edu | |
Principal Investigator: Stacy D Hunter, PhD |
Responsible Party: | Stacy Hunter, Assistant Professor, Texas State University |
ClinicalTrials.gov Identifier: | NCT05353270 |
Other Study ID Numbers: |
7620 |
First Posted: | April 29, 2022 Key Record Dates |
Last Update Posted: | April 29, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Blood pressure Salt sensitivity |